Increasing Incidence of Cancer is Propelling the Growth of Cancer Supportive Care Drugs Industry

Published Date : 20 Apr 2023

The global cancer supportive care drugs industry revenue was estimated at USD 20.96 billion in 2022 and it is expected to increase to around USD 25.78 billion by 2032 with a CAGR of roughly 2.09% between 2023 and 2032.

The cancer supportive care drugs industry growth is driven by the rising prevalence of cancer, increasing geriatric population, increasing government expenditure on healthcare, growing disposable income, and high adoption of chemotherapy in developing regions.

Industry Overview:

Cancer patients who have had an adverse reaction to chemotherapy may be given medicines or additional treatments as part of supportive care. The supportive care drugs for cancer patients can be administered at any time of the disease; they stay with cancer patients throughout their treatment, especially assisting them in managing the side effects associated with chemotherapy. The healthcare system has recently begun giving cancer-supportive care medicines or drugs to severely sick patients at the start of their cancer therapy to reduce the possibility of negative side effects in the future. 

Regional Insights:

North America is expected to dominate the industry during the forecast period. The growth in the region is attributed to the growing prevalence of cancer and the numerous side effects associated with cancer therapy. According to the American Cancer Society, in 2022, around 1.9 million new cancer cases were diagnosed and 609,360 cancer deaths in the US. Moreover, the growing geriatric population is also one of the major influencing factors for the industry growth over the projected period. 

In the United States, there were 54.1 million people 65 and elderly as of 2019. More than one in seven Americans made up 16% of the population, represented. Since 2009, there have been 14.4 million more older Americans than there were in 2009 (a 36 percent increase), versus a 3% increase in the population under 65. Furthermore, the increasing research and development expenditure provides a lucrative opportunity for industry expansion.

The Asia Pacific is expected to grow at the highest CAGR during the forecast period. The regional growth is driven by the growing prevalence of cancer particularly in the countries like India and China. According to the Indian Council for Medical Research, the number of cancer patients in India is expected to rise from 26.7 million in 2021 to 29.8 million in 2025. 

The Northeast and the North had the greatest prevalence last year (2,408 patients per 100,000). (2,177 per 100,000). Seven cancers accounted for more than 40% of the total disease burden: lung (10.6%), breast (10.5%), mouth (5.7%), liver (4.6%), esophagus (5.8%), stomach (5.2%), and cervix uteri (4.3%). Furthermore, the growing side effects associated with cancer therapy are expected to drive industry growth in the region.

Cancer Supportive Care Drugs Industry Report Scope:

Report Coverage Details
Market Size in 2022 USD 20.96 Billion
Projected Forecast Value in 2032 USD 25.78 Billion
Growth Rate 2.09% from 2023 to 2032
Fastest Growing Market Asia Pacific
Largest Market North America
Base Year 2022
Forecast Period 2023 to 2032
Regions Covered North America, Europe, Asia-Pacific, Latin America and Middle East & Africa

Report Highlights:

  • By therapeutic class, the Granulocyte Colony Stimulating Factor (G-CSF) segment is expected to dominate the industry during the forecast period. It is the primary option for treating neutropenia brought on by cancer. For lymphoma and breast tumors, it is one of the most commonly given palliative care drugs. For instance, G-CSF is administered to 84% of lymphoma patients and 70% of breast cancer patients in the UK, respectively. However, the declining use of myelosuppressive chemotherapy due to the rise of Immuno-Oncology (IO) medications, such as anti-PD-1/L1s, restricts the production of G-CSF. Thus, driving segmental growth.
  • By application, the breast cancer segment is expected to capture the largest industry share during the projected period owing to the growing prevalence of breast cancer among women across the globe. Worldwide, breast cancer causes more neglected disability-adjusted life years (DALYs) for women than any other form of cancer.  Every nation in the world experiences breast cancer in women after adolescence at any age, though the incidence rates rise as people age. Thus, this is expected to drive segmental growth.
  • By distribution channel, the hospital pharmacy segment is expected to capture the largest industry share during the projected period. The hospital pharmacy's capacity to provide patients with specialized medication plans for cancer patients is what fuels the segment's expansion. Additionally, it has been noted that the growing hospitalization of cancer patients in facilities with sophisticated care settings is a key factor in the hospital pharmacy segment's development. Besides, the online pharmacy is expected to grow at the highest CAGR over the forecast period owing to the growing demand for convenient prescription drug delivery.

Industry Dynamics:


Rising prevalence of cancer along with the increasing geriatric population

Age-related rises in cancer incidence are observed. At the age of 60 or higher, more than one thousand per one lakh people acquire cancer, according to the National Institute of Cancer. The demand for cancer supportive care medications has been seen to increase due to the increasing rates of colorectal, lung, and gastric cancer in the elderly population. 

The elderly population (those over 65) is more susceptible to chronic illnesses, including cancer, because of the rising number of damaged cells and decreased immunity. Older patients may find cancer treatment to be complex and difficult because their bodies react to therapy less favorably; difficult cancer therapies may be intolerable to them. Therefore, in comparison to the younger population, cancer supportive care medications and hospice care are strongly advised for the elderly population.


Rising deployment of targeted therapies in cancer treatment

Advanced cancer treatment known as "targeted therapy" aims to stop the development of cancer cells. The use of the medicine or treatment is widespread due to its unparalleled advantages for cancer patients. Targeted treatments have several benefits, which the oncology industry has recently discovered through appropriate clinical studies. Targeted treatment, as opposed to chemotherapy, can rapidly find cancer cells and eliminate them without causing damage to healthy cells or organs. 

Additionally, this treatment is less uncomfortable and has relatively fewer adverse effects. Growing clinical studies and the use of tailored treatments for cancer patients will greatly reduce the use of chemotherapy globally, which is expected to have a negative impact on the industry for cancer supportive care medications during the projection period.


The rising government focus on improving the oncology sector

Governments around the world are concentrating on improving the general infrastructure of the oncology sector to deliver high-quality healthcare services to cancer patients in light of the growing public health worries. Many governments all over the world are investing in new cancer treatment centers and centralized buying programs. 

For instance, England has established a 10-year long-term strategy for cancer to increase cancer patients' chances of survival by 55% before 2028. The Indian government is also presently concentrating on increasing the number of linear accelerators needed for radiation treatment. There are numerous chances for researchers to develop cutting-edge supportive care medicines for cancer patients as a result of the growing government emphasis and expenditure on advancing the oncology sector.

Recent Developments:

  • In June 2022, a collaboration between EVERSANA and Accord biopharmaceutical enabled the release of CAMCEVI® (leuprolide) 42mg injection emulsion for the therapy of metastatic prostate cancer in males.

Major Key Players:

  • Merck & Co.
  • Novartis AG
  • F. Hoffman-La Roche AG
  • Johnson & Johnson
  • GlaxoSmithKline Plc
  • Helsin Healthcare SA
  • Baxter International Inc

Market Segmentation:

By Therapeutic Class

  • ESA (Erythropoiesis Stimulating Agents)
  • G-CSFs (Granulocyte Colony Stimulating Factors)
  • Antiemetics
  • Bisphosphonates
  • Opioids
  • NSAIDs (Non-Steroidal Auto Inflammatory Drugs)

By Application

  • Breast Cancer
  • Stomach Cancer
  • Colorectal Cancer
  • Liver Cancer
  • Prostate Cancer

By Distribution Channel

  • Drug pharmacies/ Retail pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

Buy this Research Report@

You can place an order or ask any questions, please feel free to contact at | +1 9197 992 333